« Back to Record
Brandão, M., Hiltermann, J., Wauters, E., Solomon, B., Castanon Alvarez, E., Felip, E., Gort, E., Izumi, H., Kim, D. W., Paz Ares, L., Rohrberg, K., Steinbusch, L., Yoshida, T., Chen, H., Colebrook, S., Achour, I., Origuchi, M., Aroldi, F., & Cho, B. (2023). 1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01. Annals of oncology, 34, S822-S823. doi:10.1016/j.annonc.2023.09.2477
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401702



